Mr. Dr. Andre Boulet reports

DEVONIAN REPORTS RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

Devonian Health Group Inc. highlights the results of its annual general and special meeting of shareholders held on March 27, 2026, on-line via live webcast. Shareholders voted on, and approved, the following proposals at the meeting.

Election of directors

Taking into account the proxies received and the votes cast at the meeting, the following individuals have been elected as directors of the company until the next annual shareholders meeting: Dr. Andre P. Boulet, Luc Buisson, Pr. Louis Flamand, Kathryn J. Gregory, Pierre Labbe, Josh Muntner, Dr. Kira Sheinerman and Dennis Turpin.

Dr. Boulet, chairman and chief executive officer, mentioned: "We are pleased to welcome Josh, Kira and Luc to our board. Their extensive experience and strategic insight in financing strategy will be invaluable as we continue to execute on our growth strategy and create long-term value for our shareholders."

Mr. Muntner is a seasoned biopharmaceutical finance executive with over 25 years of experience as a chief financial officer and investment banker. He has led more than 90 financings and strategic transactions, raising over $9-billion in capital. Mr. Muntner has held senior leadership roles across private and public life sciences companies, with responsibility for global finance, investor relations and capital markets strategy. He holds a MBA from UCLA Anderson School of Management and a BFA from Carnegie Mellon University.

Dr. Sheinerman is a managing director of investment banking at H.C. Wainwright and co-founder of DiamiR Biosciences. She brings deep expertise in health care financing, strategic advisory and operations. She holds a PhD in biomedical sciences from Mount Sinai School of Medicine and an honours MBA from Baruch College.

Mr. Buisson is a senior strategic and financial adviser with over 35 years of experience in global investment banking and corporate finance. He previously served as vice-chair at HSBC across Canada and the Americas, advising governments, corporations, pension funds and institutional investors on M&As (mergers and acquisitions), capital markets and strategic transactions totalling more than $200-billion. Mr. Buisson is recognized for his sound judgment and ability to navigate complex stakeholder environments, providing pragmatic advice to boards and senior executives on mergers and acquisitions, capital structure, and transaction execution.

The company also extends its sincere thanks to David Baker, Edouard Dahl and Luc Gregoire for their dedicated services and contributions to the board over the past years.

Appointment of auditor

Taking into account the proxies received and the votes cast at the meeting, MNP LLP has been appointed as the independent auditor of the company for the current fiscal year ending July 31, 2026, and the directors of the company have been authorized to determine its remuneration.

Option plan amendment

Under the TSX Venture Exchange policies, the stock option plan of the company is a "fixed up to 20 per cent" plan and any amendments must be approved by disinterested shareholders at a general meeting of the company. The amendment aimed to increase the number of common shares in the capital of the company reserved for issuance under the option plan, from 29,644,506 shares on a preconsolidation basis (representing approximately 494,075 on a postconsolidation basis) to 553,146 shares on a postconsolidation basis, so that it would represent 20 per cent of the issued and outstanding shares. At the meeting, disinterested shareholders approved the amendment to the option plan.

The full text of the option plan can be found in Schedule B of the company's management and information circular, a copy of which can be found on the company's SEDAR+ profile. The option plan remains subject to the final approval of the exchange.

About Devonian Health Group Inc.

Devonian is a clinical-stage pharmaceutical company specializing in the development of drugs for various auto-immune fibro-inflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibro-inflammatory autoimmune diseases, including, but not limited to, atopic dermatitis, radiodermatitis and ulcerative colitis.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Group LP, focused on selling prescription pharmaceutical products in Canada, under licences from brand name pharmaceutical companies.

Devonian was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange and currently quoted on the OTCQB Venture Market.

We seek Safe Harbor.